Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.
Wolfe Research analyst Alexandria Hammond initiated coverage of Moderna (MRNA) with an Underperform rating and $40 price target Moderna may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback